GILEAD Sciences has announced that combination drug Vosevi (sofosbuvir with velpatasvir and voxilaprevir), the first single tablet for the re-treatment of chronic hepatitis C infection in adults who have failed previous treatment with direct-acting antivirals, was added to the ARTG yesterday.
The above article was sent to subscribers in Pharmacy Daily's issue from 29 Mar 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Mar 18
